查看文章

The peripheral T-cell lymphomas (PTCL) are a heterogeneous group of hematologic malignancies, which represent about 10-15% of all non-Hodgkin lymphomas (NHL) in Western populations [1]. With the exception of anaplastic large cell lymphoma (ALCL), the outcome of frontline chemotherapy regimens has been discouraging for most PTCL subtypes, with reported long-term survival of only 20-30%[2]. In one of the largest population registry studies of PTCL patients, 84% of patients who received either CHOP or CHOEP as initial chemotherapy had a median overall survival (OS) of only 2.5 months [3]. Most patients will relapse, and four histone deacetylase inhibitors (HDACi) have been approved globally for patients with relapsed or refractory (R/R) PTCL. Belinostat, a hydroxamic-acid-based HDACi, was the second HDACi to receive FDA accelerated approval for the treatment of R/R PTCL. In the registration …